NYU Langone's Perlmutter Cancer Center | Strategic Alliance Partners

April 03, 2025

Bhavana Pothuri, MD, and Tiffany Redfern, MD, FACOG, discuss updates in ovarian cancer from the 2025 SGO Annual Meeting.

April 03, 2025

Bhavana Pothuri, MD, and Tiffany Redfern, MD, FACOG, discuss other potential roles for mirvetuximab soravtansine in ovarian cancer.

April 03, 2025

Bhavana Pothuri, MD, and Tiffany Redfern, MD, FACOG, on patient-reported outcome data for mirvetuximab soravtansine in platinum-resistant ovarian cancer.

April 03, 2025

Bhavana Pothuri, MD, and Tiffany Redfern, MD, FACOG, on final overall survival data for mirvetuximab soravtansine in platinum-resistant ovarian cancer.

March 31, 2025

Bhavana Pothuri, MD, and Tiffany Redfern, MD, FACOG, discuss current treatment approached in platinum-resistant ovarian cancer.

February 14, 2025

Bhavana Pothuri, MD, discusses the current treatment paradigm in endometrial cancer and the targeted therapies currently being investigated.

October 30, 2024

Marc J. Braunstein, MD, PhD, discusses VOD risk factors, management strategies, and prevention strategies in the post-HSCT hematologic malignancy setting.

August 19, 2024

Jeffrey S. Weber, MD, PhD, inductee of the 2016 Giants of Cancer Care award in Melanoma, has died.

July 25, 2024

Joshua K. Sabari, MD, discusses barriers to biomarker testing in patients with non–small cell lung cancer.

June 27, 2024

Bhavana Pothuri, MD, discusses real-world treatment patterns and outcomes in patients with advanced endometrial cancer according to MMR/MSI status.

May 22, 2024

Michelle Krogsgaard, PhD, discusses the identification and potentially utility of phosphorylated neoantigen targets for anticancer vaccine development.

April 23, 2024

Marc J. Braunstein, MD, PhD, FACP, of NYU Grossman Long Island School of Medicine, discusses lessons learned with program building and medical education with hematologic cancers.

March 29, 2024

Joshua K. Sabari, MD, discusses the FDA approval of frontline amivantamab plus chemotherapy for NSCLC harboring EGFR exon 20 insertion mutations.

March 13, 2024

First-line niraparib maintenance was not associated with worsened health-related quality of life outcomes vs placebo in advanced ovarian cancer.

February 26, 2024

Joshua K. Sabari, MD, reviews data from the 5-year overall survival update from the POSEIDON study investigating durvalumab, tremelimumab, and chemotherapy in first-line metastatic non–small cell lung cancer.

February 15, 2024

Joshua K. Sabari, MD, discusses updates in ADCs in NSCLC.

February 14, 2024

Joshua K. Sabari, MD, explains the utility of ADCs in patients with NSCLC and their benefit in patients with EGFR-, ALK-, or HER2-mutant disease.

February 09, 2024

Joshua K. Sabari, MD, discusses the investigation of patritumab deruxtecan in EGFR-mutant non–small cell lung cancer.

February 08, 2024

Jeffrey S. Weber, MD, PhD, discusses the background for the KEYNOTE-942 trial, which was conducted in resected high-risk melanoma.

January 19, 2024

Nina D'Abreo, MD, discusses the importance of considering a patient’s medical history and preferences when deciding on a treatment course in HER2-positive breast cancer and highlights the important role of surgeons within breast cancer treatment.